Free Trial

Bausch Health Cos (BHC) Competitors

Bausch Health Cos logo
$6.95 -0.17 (-2.40%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$6.96 +0.01 (+0.09%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BHC vs. BPMC, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and LNTH

Should you be buying Bausch Health Cos stock or one of its competitors? The main competitors of Bausch Health Cos include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

Bausch Health Cos vs. Its Competitors

Blueprint Medicines (NASDAQ:BPMC) and Bausch Health Cos (NYSE:BHC) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

78.7% of Bausch Health Cos shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 8.1% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Blueprint Medicines currently has a consensus price target of $128.06, indicating a potential downside of 0.16%. Bausch Health Cos has a consensus price target of $7.42, indicating a potential upside of 6.73%. Given Bausch Health Cos' higher possible upside, analysts plainly believe Bausch Health Cos is more favorable than Blueprint Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines
0 Sell rating(s)
17 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.27
Bausch Health Cos
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86

Bausch Health Cos has higher revenue and earnings than Blueprint Medicines. Bausch Health Cos is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$508.82M16.28-$67.09M-$2.47-51.93
Bausch Health Cos$9.63B0.27-$46M-$0.11-63.17

Bausch Health Cos has a net margin of -0.41% compared to Blueprint Medicines' net margin of -27.70%. Blueprint Medicines' return on equity of -64.60% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Blueprint Medicines-27.70% -64.60% -17.22%
Bausch Health Cos -0.41%-540.45%5.26%

In the previous week, Blueprint Medicines had 4 more articles in the media than Bausch Health Cos. MarketBeat recorded 5 mentions for Blueprint Medicines and 1 mentions for Bausch Health Cos. Blueprint Medicines' average media sentiment score of 0.81 beat Bausch Health Cos' score of 0.23 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Blueprint Medicines
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bausch Health Cos
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Blueprint Medicines has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Summary

Blueprint Medicines beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

Get Bausch Health Cos News Delivered to You Automatically

Sign up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BHC vs. The Competition

MetricBausch Health CosMED IndustryMedical SectorNYSE Exchange
Market Cap$2.57B$3.94B$5.53B$20.65B
Dividend YieldN/A1.16%5.22%3.72%
P/E Ratio-63.177.5127.7028.08
Price / Sales0.2711.19419.5638.45
Price / Cash0.916.5826.2118.22
Price / Book-7.812.698.034.61
Net Income-$46M-$109.62M$3.18B$983.39M
7 Day Performance4.03%2.98%2.88%2.57%
1 Month Performance46.29%6.25%1.67%5.08%
1 Year Performance-3.89%31.83%34.39%15.10%

Bausch Health Cos Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BHC
Bausch Health Cos
3.0632 of 5 stars
$6.95
-2.4%
$7.42
+6.7%
-3.9%$2.57B$9.63B-63.1720,700
BPMC
Blueprint Medicines
1.5353 of 5 stars
$128.18
+0.1%
$128.06
-0.1%
+14.8%$8.28B$562.12M-51.89640
BBIO
BridgeBio Pharma
4.6882 of 5 stars
$43.18
-3.7%
$58.85
+36.3%
+69.7%$8.20B$221.90M-12.23400High Trading Volume
VRNA
Verona Pharma PLC American Depositary Share
2.7874 of 5 stars
$94.58
+0.8%
$101.10
+6.9%
+466.0%$8.05B$42.28M-47.2930Positive News
ROIV
Roivant Sciences
1.5178 of 5 stars
$11.27
-1.1%
$17.50
+55.3%
+1.8%$7.66B$29.05M-45.08860
ELAN
Elanco Animal Health
2.3831 of 5 stars
$14.29
flat
$15.17
+6.1%
+3.0%$7.10B$4.44B19.319,000Analyst Upgrade
RVMD
Revolution Medicines
4.5774 of 5 stars
$36.79
-0.3%
$67.58
+83.7%
-1.4%$6.85B$11.58M-9.20250
LEGN
Legend Biotech
3.0923 of 5 stars
$35.49
+2.5%
$76.20
+114.7%
-23.7%$6.52B$627.24M-60.152,609Positive News
GRFS
Grifols
4.1158 of 5 stars
$9.04
+2.0%
$10.30
+13.9%
+28.9%$6.22B$7.81B7.7323,822News Coverage
Analyst Upgrade
TGTX
TG Therapeutics
3.2906 of 5 stars
$35.99
-2.0%
$40.80
+13.4%
+95.7%$5.71B$386.39M149.96290
LNTH
Lantheus
4.4551 of 5 stars
$81.86
+0.5%
$130.50
+59.4%
+0.4%$5.66B$1.53B23.26700Positive News

Related Companies and Tools


This page (NYSE:BHC) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners